How Will Demands For Effectiveness Evidence Change Drug Development

The project reported in this Occasional Paper was intended to determine how changing demands for evidence are affecting drug development in five global pharmaceutical companies: Amgen, Eli Lilly, GSK, Novartis and Sanofi-Aventis. Read more here. (Source: OHE, 4/23/14).

You might also be interested in:

23andME CEO Talks Privacy, Deal with GSK September 11, 2018
Express Scripts: Fix Broken Pricing Model April 25, 2018
FDA OKs Amgen’s Migraine Drug May 18, 2018
Abarca, Amgen OK Outcomes-Based Deal for Repatha February 23, 2018
Report: Eli Lilly Ignoring California’s Price Hike Notice Law August 11, 2018
Eli Lilly CEO Details Steps to Drive Down Health Costs August 28, 2018
Former Pfizer Exec: Value-Based Contracts Should be Norm, Not Anomaly May 4, 2018